Insider Transactions in Q2 2024 at Kinnate Biopharma Inc. (KNTE)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 03
2024
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,578
-100.0%
|
-
|
|
Apr 03
2024
|
Keith T. Flaherty |
SELL
Sale (or disposition) back to the issuer
|
Direct |
66,377
-100.0%
|
-
|
|
Apr 03
2024
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,087
-100.0%
|
-
|
|
Apr 03
2024
|
Nima Farzan CHIEF EXECUTIVE OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,186
-100.0%
|
-
|
|
Apr 03
2024
|
James B. Tananbaum |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
13,718,311
-100.0%
|
-
|
|
Apr 03
2024
|
Carl L Gordon Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,009,729
-100.0%
|
-
|
|
Apr 03
2024
|
Orbimed Advisors LLC Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,009,729
-100.0%
|
-
|
|
Apr 03
2024
|
Foresite Capital Management Iv, LLC > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
13,718,311
-100.0%
|
-
|